Rocket One Inc (HOTH)Healthcare | Biotechnology | Hoboken, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 5:34 a.m. UTC
The stock is currently trapped in a severe structural decline with no path to recovery. Despite a recent surge driven by a pivot to AI and space computing, the underlying business is fundamentally broken, reporting negative earnings, negative free cash flow, and negative returns on both assets and equity. The balance sheet shows significant operational burn with no visible profitability horizon. Furthermore, the price action confirms this deterioration: the asset is trading well below its 200-day moving average, indicating that the market has already priced out the speculative hype. With no analyst coverage, no institutional recommendations, and a complete lack of dividend history or payout capability, this represents a high-risk speculative vehicle rather than an investment opportunity. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.092 |
| Market Cap | 26,013,596 |
| Forward P/E | -1.92 |
| Beta | 0.58 |
| Website | https://hoththerapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7685951 |
| Address1 | 720 Monroe Street |
| Address2 | Suite E514 |
| All Time High | 347.0 |
| All Time Low | 0.4894 |
| Ask | 1.47 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 38,430,177 |
| Average Volume | 8,119,849 |
| Average Volume10Days | 38,430,177 |
| Beta | 0.576 |
| Bid | 1.36 |
| Bid Size | 200 |
| Book Value | 0.396 |
| City | Hoboken |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 1.36 |
| Current Ratio | 4.724 |
| Date Short Interest | 1,777,507,200 |
| Day High | 1.36 |
| Day Low | 1.36 |
| Debt To Equity | 0.092 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 4,049,304 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 0.80349 |
| Fifty Two Week High | 2.45 |
| Fifty Two Week Low | 0.4894 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 15,787,156 |
| Forward Eps | -0.71 |
| Forward P E | -1.915493 |
| Free Cashflow | -5,543,313 |
| Full Time Employees | 2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.02894 |
| Held Percent Institutions | 0.041139998 |
| Implied Shares Outstanding | 19,127,643 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,666,742,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is based in Hoboken, New Jersey. |
| Long Name | Rocket One Inc |
| Market Cap | 26,013,596 |
| Max Age | 86,400 |
| Message Board Id | finmb_434856528 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -12,469,302 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 18,919,671 |
| Open | 0.8685 |
| Operating Cashflow | -9,803,918 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 866 239 7459 |
| Previous Close | 1.36 |
| Price Hint | 4 |
| Price To Book | 3.4343436 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.301 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 1.36 |
| Regular Market Day Low | 1.36 |
| Regular Market Open | 0.8685 |
| Regular Market Previous Close | 1.36 |
| Regular Market Volume | 135,373,627 |
| Return On Assets | -1.00885 |
| Return On Equity | -1.91399 |
| Sand P52 Week Change | 0.21718061 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,127,643 |
| Shares Percent Shares Out | 0.0417 |
| Shares Short | 797,306 |
| Shares Short Previous Month Date | 1,774,915,200 |
| Shares Short Prior Month | 749,807 |
| Short Name | Hoth Therapeutics, Inc. |
| Short Percent Of Float | 0.0429 |
| Short Ratio | 0.13 |
| State | NJ |
| Symbol | HOTH |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 6,247,467 |
| Total Cash Per Share | 0.384 |
| Total Debt | 5,678 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.8 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 1.1099426 |
| Underlying Symbol | HOTH |
| Uuid | ff6dafe1-fa0d-3a83-9121-424872ea93bf |
| Volume | 135,373,627 |
| Website | https://hoththerapeutics.com |
| Zip | 7,030 |